Mesenchymal Stem Cell Soluble Mediators and Cystic Fibrosis

Area of Science:

• Regenerative Medicine
• Immunology
• Pulmonary Medicine

Background:

• Cystic Fibrosis (CF) is a genetic disorder characterized by chronic pulmonary infection and inflammation, leading to significant morbidity and mortality.
• Human Mesenchymal stem cells (hMSCs) possess anti-inflammatory and antimicrobial properties.
• Previous studies demonstrated hMSC efficacy in reducing inflammation and *Pseudomonas aeruginosa* infection in a murine CF model.

Purpose of the Study:

• To elucidate the mechanisms by which hMSCs improve outcomes in the CF mouse model.
• To investigate how hMSC-secreted products modulate the inflammatory response to pathogenic organisms, specifically *Pseudomonas aeruginosa*.
• To determine if hMSCs regulate peroxisome proliferator activator receptor gamma (PPARγ) to decrease inflammation.

Main Methods:

• Utilized an *in vivo* murine model of Cystic Fibrosis (CF) infection and inflammation.
• Administered hMSC-derived products (supernatants) to the CF model.
• Assessed the impact of hMSCs on inflammation and *Pseudomonas aeruginosa* infection levels.
• Investigated the role of peroxisome proliferator activator receptor gamma (PPARγ) in mediating hMSC anti-inflammatory effects.

Main Results:

• hMSC-secreted products demonstrated anti-inflammatory effects in the context of chronic pulmonary infections.
• hMSCs were shown to decrease inflammation and *Pseudomonas aeruginosa* infection in the CF mouse model.
• Evidence suggests hMSCs may impact the inflammatory response through PPARγ regulation.

Conclusions:

• hMSC-secreted products offer a therapeutic potential for managing inflammation and infection in Cystic Fibrosis.
• The anti-inflammatory effects of hMSCs in CF may be mediated, in part, by the regulation of PPARγ.
• Further research into hMSC-based therapies could lead to improved treatments for CF lung disease.